Dimesna与癌症化疗药物联合使用以降低尿毒性。
Dimesna is an uroprotective agent used to decrease urotoxicity.
552 nM
12 或 35 mg/kg 口服每周五次
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Parker AR, et al. Mol, Cancer Ther, 2010, 9(9), 2558-2567.
[2] Hausheer FH, et al.Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 2010 Apr;65(5):941-951.
分子式 C4H8Na2O6S4 |
分子量 326.34 |
CAS号 16208-51-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 65 mg/mL |
Water 65 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00966914 | Non-small Cell Lung Cancer | Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel | BioNumerik Pharmaceuticals, Inc. | Phase 3 | 2010-04-01 | 2017-01-09 |
NCT00039780 | Breast Neoplasms|Breast Diseases|Metastases, Neoplasm | Drug: BNP7787|Drug: Placebo | BioNumerik Pharmaceuticals, Inc. | Phase 3 | 2001-09-01 | 2017-01-09 |
NCT00003569 | Head and Neck Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer | Drug: cisplatin|Drug: dimesna|Drug: paclitaxel | Roswell Park Cancer Institute|National Cancer Institute (NCI) | Phase 1 | 1998-03-01 | 2013-01-30 |
NCT00077311 | Anemia|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Neutropenia | Biological: darbepoetin alfa|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Drug: BNP7787 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Phase 2 | 2004-08-01 | 2016-06-28 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们